197785-23-2

Usage

Class

Diphenyl ethers (aromatic compounds with two benzene rings linked by an ether group)

Function

Nonsteroidal anti-inflammatory drug (NSAID)

Uses

Relieves mild to moderate pain, reduces inflammation, treats arthritis

Mechanism

Inhibits the production of prostaglandins (chemicals causing pain and inflammation)

Form

Tablet

Tolerance

Generally well-tolerated

Side effects

Gastrointestinal irritation, dizziness, headache

Usage instructions

Follow directions provided by a healthcare professional

Upstream product

• 32085-88-4 3,5-difluorobenzaldehyde 
• 107-21-1 ethylene glycol 

Downstream Products

• 717883-47-1 4-[1,3]dioxolan-2-yl-2,6-difluoro-benzonitrile 
• 197785-24-3 2-(4-bromo-3,5-difluorophenyl)-1,3-dioxolane 
• 433939-88-9 2,6-difluoro-4-formylbenzonitrile 

Relevant academic research and scientific papers

A fluorine scan of the phenylamidinium needle of tricyclic thrombin inhibitors: Effects of fluorine substitution on pKa and binding affinity and evidence for intermolecular C-F...CN interactions

The H-atoms of the phenylamidinium needle of tricyclic thrombin inhibitors, which interacts with Asp189 at the bottom of the selectivity pocket S1 of the enzyme, were systematically exchanged with F-atoms in an attempt to improve the pharmacokinetic prope

Inhibition by Water during Heterogeneous Br?nsted Acid Catalysis by Three-Dimensional Crystalline Organic Salts

A new self-assembled and self-healing class of metal free, recyclable, heterogeneous Br?nsted acid catalysts has been developed by the protonation of aniline derivatives (tetrakis(4-aminophenyl)methane, leuco-crystal violet, benzidine, and p-phenylenediamine) with aromatic sulfonic acids (tetrakis(phenyl-4-sulfonic acid)methane, and 2,6-naphthalenedisulfonic acid). As a result, five three-dimensional crystalline organic salts (F-1a, F-1b, F-1c, F-2, and F-3) were obtained, linked by hydrogen bonds and additionally stabilized by the opposite charges of the components. Frameworks F-2 and F-3 were prepared for the first time and characterized by elemental analysis, X-ray structural analysis (for F-2), thermogravimetry, SEM, and FTIR spectroscopy. The catalytic activities of crystalline organic salts F-1-3 have been explored in industrially important epoxide ring-opening and acetal formation reactions. The presence of encapsulated water inside frameworks F-1a and F-2 had an inhibitory effect on the performance of the catalysts. X-ray diffraction analysis of hydrated and dehydrated samples of F-1a and F-2 indicated that water of crystallization served as a cross-linking agent, diminishing the substrate induced "breathing"affinities of the frameworks.

HETEROCYCLIC COMPOUND INTERMEDIATE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF

Disclosed by the invention is a heterocyclic compound, an intermediate, and a preparation method therefor and an application thereof. Provided by the invention are a heterocyclic compound as shown in formula I, and a stereoisomer, a geometric isomer, a tautomer, a nitrogen oxide, a hydrate, a solvate, a metabolite, an ester, a pharmaceutically acceptable salt or a prodrug thereof. The heterocyclic compound hasa high P2X3 antagonistic activity, and has good selectivity, low toxicity, good metabolic stability and little taste influence.

NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS FOR OPIOID RECEPTORS

This invention relates to novel compounds which are antagonists or inverse agonists at one or more of the opioid receptors, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy.